Botulinum Toxins

• 

  Subject Areas on Research

  • A continuing common-source outbreak of botulism in a family. 
  • A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. 
  • Adenovirus F protein as a delivery vehicle for botulinum B. 
  • Aspartate release from rat hippocampal synaptosomes. 
  • Botulinum toxin for blepharospasm: single-fiber EMG studies. 
  • Botulinum toxin in the management of blepharospasm. 
  • Botulinum toxin in the treatment of tics. 
  • Botulinum toxin injection for postlaryngectomy tracheoesophageal speech failure. 
  • Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. 
  • Botulinum toxin therapy for neurologic disorders. 
  • Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. 
  • Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. 
  • Cellular cytoskeleton dynamics modulates non-viral gene delivery through RhoGTPases 
  • Clinical Practice Guideline for the Management of Anal Fissures. 
  • Contemporary solutions for the treatment of facial nerve paralysis. 
  • Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. 
  • Current trends in botulism in the United States. 
  • Elbow tendinopathy and tendon ruptures: epicondylitis, biceps and triceps ruptures. 
  • Epidemiologic, clinical and laboratory aspects of wound botulism. 
  • Evaluation of the use of botulinum toxin in children with achalasia. 
  • First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. 
  • Food-borne botulism in the United States, 1970-1975. 
  • High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. 
  • Inhibition of Rho-kinase induces alphaB-crystallin expression in lens epithelial cells. 
  • Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. 
  • Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. 
  • Management of facial spasm with Clostridium botulinum toxin. 
  • Modulation of Rho GTPase activity alleviates chondroitin sulfate proteoglycan-dependent inhibition of neurite extension. 
  • Mucosal vaccine development for botulinum intoxication. 
  • Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. 
  • New Elements To Consider When Modeling the Hazards Associated with Botulinum Neurotoxin in Food. 
  • Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results. 
  • Response to Avila et al's "Dermatologist Online Ratings for Botulinum Toxin are Nuanced and May be Misleading". 
  • Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure - mechanism of action (SPONGE-HF). 
  • Technology Assessment Status Evaluation: botulinum toxin therapy in gastrointestinal endoscopy. November, 1996. ASGE. American Society for Gastrointestinal Endoscopy. 
  • The Kv2.1 channels mediate neuronal apoptosis induced by excitotoxicity. 
  • The current treatment of achalasia. 
  • The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. 
  • Treatment of blepharospasm with botulinum toxin. 
  • Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. 
  • Use of botulinum toxin in strabismus after retinal detachment surgery. 
  • Vertical rectus muscle transposition with intraoperative botulinum injection for treatment of chronic sixth nerve palsy. 
  • rac, a novel ras-related family of proteins that are botulinum toxin substrates.